Insider Selling: uniQure (NASDAQ:QURE) CFO Sells $153,448.70 in Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 14,341 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the transaction, the chief financial officer now owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This represents a 8.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Christian Klemt also recently made the following trade(s):

• On Thursday, February 27th, Christian Klemt sold 2,916 shares of uniQure stock. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The shares were sold at an average price of $7.55, for a total value of $13,559.80.

uniQure Stock Up 8.9 %

uniQure stock opened at $13.15 on Friday. The company has a market capitalization of $640.73 million, a P/E ratio of -2.65 and a beta of 0.38. The firm’s fifty day simple moving average is $15.05 and its 200-day simple moving average is $9.81. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on QURE shares. Guggenheim reissued a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Wells Fargo & Company cut their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday. Leerink Partners boosted their price target on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. HC Wainwright upped their price objective on uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Finally, Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.89.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 969 shares during the period. Tudor Investment Corp ET AL raised its holdings in uniQure by 5.9% in the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after acquiring an additional 1,371 shares during the period. Wells Fargo & Company MN raised its holdings in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after acquiring an additional 1,503 shares during the period. Northern Trust Corp raised its holdings in uniQure by 2.1% in the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after acquiring an additional 1,923 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in uniQure by 6.0% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock worth $1,253,000 after acquiring an additional 3,996 shares during the period. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.